Leads and Contacts--July 2007
This article was originally published in RPM Report
Executive Summary
Key figures involved in the EPO safety debate from FDA and CMS; the Zimulti advisory committee review; and the Senate drafting of the FDA legislation.
You may also be interested in...
House Credit for FDAAA
Key House staffers on the Food & Drug Administration Amendments of 2007 are identified. Key negotiators for FDA and the biotech industry on the failed follow-on biologics effort are also identified.
House Credit for FDAAA
Key House staffers on the Food & Drug Administration Amendments of 2007 are identified. Key negotiators for FDA and the biotech industry on the failed follow-on biologics effort are also identified.
Sanofi-Aventis' Zimulti: Knowing When to Say When
Rimonabant had all the early signs of a mega-blockbuster. But behind that shiny veneer was a drug with a serious risk profile-one that mimicked the suicidality rates of the SSRI class. That made rimonabant an enormous red flag for FDA reviewers. Why didn't Sanofi-Aventis see it coming?